Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846515 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
A Phase 3 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT06846515 is a Phase 3 study of Gout and Hyperuricemia that is active but no longer recruiting, run by Arthrosi Therapeutics. The registered enrollment target is 750 participants, below the 8,866-participant average among 34 other Gout trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06846515, a Phase 3 study of Gout and Hyperuricemia, is active but no longer recruiting, sponsored by Arthrosi Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AR882 75 mg
- DRUG AR882 50 mg
Study Locations (20)
California
- Arthrosi Investigative Site (614) - Garden Grove
- Arthrosi Investigative Site (618) - La Mesa
- Arthrosi Investigative Site (687) - La Mesa
- Arthrosi Investigative Site (655) - La Palma
- Arthrosi Investigative Site (632) - Lincoln
- Arthrosi Investigative Site (605) - Lomita
- Arthrosi Investigative Site (675) - Long Beach
- Arthrosi Investigative Site (603) - Santa Monica
- Arthrosi Investigative Site (672) - Tarzana
- Arthrosi Investigative Site (656) - Thousand Oaks
Colorado
- Arthrosi Investigative Site (660) - Aurora
- Arthrosi Investigative Site (669) - Colorado Springs
- Arthrosi Investigative Site (612) - Fort Collins
Alabama
- Arthrosi Investigative Site (620) - Birmingham
- Arthrosi Investigative Site (616) - Huntsville
Arizona
- Arthrosi Investigative Site (680) - Peoria
- Arthrosi Investigative Site (640) - Phoenix
Florida
- Arthrosi Investigative Site (665) - Cooper City
- Arthrosi Investigative Site (613) - Jupiter
Arkansas
- Arthrosi Investigative Site (617) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846515
The ClinicalTrials.gov registry entry for NCT06846515 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,866-participant average among 34 other Gout trials with a reported enrollment target (92% lower). The listed sponsor is Arthrosi Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Gout appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06846515 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06846515 about?
NCT06846515 is a clinical study titled "Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)". This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
What is the current status of trial NCT06846515?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2025-03-11. Estimated completion is 2026-04.
What conditions does trial NCT06846515 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia, Gout Chronic, Arthritis, Gouty.
What interventions are being tested in trial NCT06846515?
The interventions under investigation include: Placebo (DRUG), AR882 75 mg (DRUG), AR882 50 mg (DRUG).
Who is sponsoring clinical trial NCT06846515?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846515 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
COMPLETED · Phase 3
-
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
COMPLETED · Phase 3
-
Combining Lesinurad With Allopurinol in Inadequate Responders
COMPLETED · Phase 3
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.